EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum IL-6 level trajectory for predicting the effectiveness and safety of tocilizumab in the treatment of refractory Takayasu arteritis

Xiaochuan Sun, Chenglong Fang, Shangyi Jin, Jing Li, Yunjiao Yang, Xiaofeng Zeng, Xinping Tian

European Journal of Internal Medicine · 2024

DOI: 10.1016/j.ejim.2024.04.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Internal Medicine, 2024. Verfasst von Xiaochuan Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing 100730, Chi…. Hauptthemen laut MEDLINE: Takayasu Arteritis, Antibodies, Monoclonal, Humanized, Interleukin-6. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: To explore the value of serial monitoring of serum interleukin-6 (IL-6) levels for predicting treatment response and occurrence of adverse events during tocilizumab (TCZ) treatment in refractory Takayasu arteritis (TAK). METHODS: TAK patients receiving TCZ treatment were prospectively recruited and followed up at 1 month, 3 months and then every 3-6 months. Serum IL-6 levels were measured at each visit. Overall response was the combination of complete and partial response, requiring resolution of signs and symptoms, hsCRP and ESR level decreased at least by half, no progression on imaging and dose of glucocorticoid

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Takayasu ArteritisAntibodies, Monoclonal, HumanizedInterleukin-6HumansFemaleMaleAdultProspective StudiesTreatment OutcomeYoung AdultMiddle AgedGlucocorticoidsBiomarkers

Stichwörter der Autor:innen

Effectiveness and safetyInterleukin-6Takayasu arteritisTocilizumab

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedInterleukin-6IL6 protein, humanGlucocorticoidsBiomarkers

Autor:innen und Institutionen

  • Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing 100730, China.
  • Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immuno…

Zitieren

APA

Sun, X., Fang, C., Jin, S., Li, J., Yang, Y., Zeng, X., & Tian, X. (2024). Serum IL-6 level trajectory for predicting the effectiveness and safety of tocilizumab in the treatment of refractory Takayasu arteritis. European Journal of Internal Medicine. https://doi.org/10.1016/j.ejim.2024.04.004

Vancouver

Sun X, Fang C, Jin S, Li J, Yang Y, Zeng X, et al. Serum IL-6 level trajectory for predicting the effectiveness and safety of tocilizumab in the treatment of refractory Takayasu arteritis. European Journal of Internal Medicine. 2024. doi:10.1016/j.ejim.2024.04.004

BibTeX
@article{Sun2024,
  author = {Sun, Xiaochuan and Fang, Chenglong and Jin, Shangyi and Li, Jing and Yang, Yunjiao and Zeng, Xiaofeng and Tian, Xinping},
  title = {Serum IL-6 level trajectory for predicting the effectiveness and safety of tocilizumab in the treatment of refractory Takayasu arteritis},
  journal = {European Journal of Internal Medicine},
  year = {2024},
  doi = {10.1016/j.ejim.2024.04.004}
}
Kostenlos starten →